Home > Journals > La Rivista Italiana della Medicina di Laboratorio > Past Issues > Articles online first > La Rivista Italiana della Medicina di Laboratorio 2021 Feb 10

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

La Rivista Italiana della Medicina di Laboratorio 2021 Feb 10

DOI: 10.23736/S1825-859X.21.00089-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: Italian

Serum calprotectin: emerging marker in rheumatoid arthritis

Maria INFANTINO , Mariangela MANFREDI

Laboratorio di Immunoallergologia, Ospedale San Giovanni di Dio, Firenze, Italia


PDF


Recent studies have well investigated serum calprotectin as a promising marker of inflammation and responsiveness to biological therapies; the molecule is involved in the recruitment of inflammatory cells by interaction with endothelial cells and directly reflects the leukocyte counts in the inflamed joints rather than systemic inflammatory activity. Compared to acute phase reactants (CRP or ESR), serum calprotectin displayes a more prompt and more marked response to inflammatory changes, thus representing a sensitive biomarker for assessing treatment responses. There is growing evidence that levels of serum calprotectin are related to clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis (RA). Circulating calprotectin levels are elevated in active RA and fall when therapy is effective and may predict future erosive damage. Laboratory studies on standardization of circulating calprotectin testing are needed due to variables such as matrix, reference values and decision cutoffs.


KEY WORDS: Serum calprotectin; Rheumatoid arthritis; Marker

top of page